

# Federica Rizzo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6069452/publications.pdf>

Version: 2024-02-01

15  
papers

610  
citations

759233

12  
h-index

996975

15  
g-index

15  
all docs

15  
docs citations

15  
times ranked

945  
citing authors

#	ARTICLE	IF	CITATIONS
1	Stathmins and Motor Neuron Diseases: Pathophysiology and Therapeutic Targets. <i>Biomedicines</i> , 2022, 10, 711.	3.2	9
2	Clinical and genetic features of a cohort of patients with MFN2-related neuropathy. <i>Scientific Reports</i> , 2022, 12, 6181.	3.3	10
3	Animal Models of CMT2A: State-of-art and Therapeutic Implications. <i>Molecular Neurobiology</i> , 2020, 57, 5121-5129.	4.0	6
4	Neural Stem Cell Transplantation for Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3103.	4.1	105
5	Disease Modeling and Therapeutic Strategies in CMT2A: State of the Art. <i>Molecular Neurobiology</i> , 2019, 56, 6460-6471.	4.0	20
6	Key role of SMN/SYNERIP and RNA-Motif 7 in spinal muscular atrophy: RNA-Seq and motif analysis of human motor neurons. <i>Brain</i> , 2019, 142, 276-294.	7.6	31
7	Downregulation of glutamic acid decarboxylase in Drosophila TDP-43-null brains provokes paralysis by affecting the organization of the neuromuscular synapses. <i>Scientific Reports</i> , 2018, 8, 1809.	3.3	17
8	Genome-wide RNA-seq of iPSC-derived motor neurons indicates selective cytoskeletal perturbation in Brown-Vialetto disease that is partially rescued by riboflavin. <i>Scientific Reports</i> , 2017, 7, 46271.	3.3	22
9	Selective mitochondrial depletion, apoptosis resistance, and increased mitophagy in human Charcot-Marie-Tooth 2A motor neurons. <i>Human Molecular Genetics</i> , 2016, 25, 4266-4281.	2.9	41
10	Spinal muscular atrophy phenotype is ameliorated in human motor neurons by SMN increase via different novel RNA therapeutic approaches. <i>Scientific Reports</i> , 2015, 5, 11746.	3.3	37
11	Gene therapy rescues disease phenotype in a spinal muscular atrophy with respiratory distress type 1 (SMARD1) mouse model. <i>Science Advances</i> , 2015, 1, e1500078.	10.3	33
12	MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives. <i>Journal of the Neurological Sciences</i> , 2015, 356, 7-18.	0.6	112
13	Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 999-1015.	5.4	89
14	Effect of Combined Systemic and Local Morpholino Treatment on the Spinal Muscular Atrophy $\hat{7}$ Mouse Model Phenotype. <i>Clinical Therapeutics</i> , 2014, 36, 340-356.e5.	2.5	44
15	iPSC-Derived Neural Stem Cells Act via Kinase Inhibition to Exert Neuroprotective Effects in Spinal Muscular Atrophy with Respiratory Distress $\hat{7}$ Type 1. <i>Stem Cell Reports</i> , 2014, 3, 297-311.	4.8	34